Seattle Genetics Inc. (NASDAQ:SGEN) Director Felix Baker bought 382,500 shares of the company’s stock in a transaction on Tuesday, November 8th. The shares were bought at an average cost of $59.36 per share, for a total transaction of $22,705,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Felix Baker also recently made the following trade(s):

  • On Thursday, November 3rd, Felix Baker bought 1,030,629 shares of Seattle Genetics stock. The shares were bought at an average cost of $56.13 per share, for a total transaction of $57,849,205.77.
  • On Tuesday, September 13th, Felix Baker bought 447,311 shares of Seattle Genetics stock. The shares were bought at an average cost of $50.71 per share, for a total transaction of $22,683,140.81.
  • On Thursday, September 8th, Felix Baker bought 414,016 shares of Seattle Genetics stock. The shares were bought at an average cost of $48.43 per share, for a total transaction of $20,050,794.88.

Shares of Seattle Genetics Inc. (NASDAQ:SGEN) opened at 68.09 on Monday. The firm’s market capitalization is $9.64 billion. Seattle Genetics Inc. has a 52-week low of $26.02 and a 52-week high of $75.36. The stock’s 50 day moving average price is $55.04 and its 200-day moving average price is $45.96.

Seattle Genetics (NASDAQ:SGEN) last issued its earnings results on Thursday, October 27th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. The firm earned $106.30 million during the quarter, compared to the consensus estimate of $4.34 million. Seattle Genetics had a negative net margin of 27.03% and a negative return on equity of 16.27%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. Equities research analysts anticipate that Seattle Genetics Inc. will post ($0.95) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its position in Seattle Genetics by 283.9% in the first quarter. BlackRock Inc. now owns 11,654 shares of the company’s stock valued at $408,000 after buying an additional 8,618 shares in the last quarter. BlackRock Group LTD increased its position in Seattle Genetics by 18.4% in the first quarter. BlackRock Group LTD now owns 102,261 shares of the company’s stock valued at $3,589,000 after buying an additional 15,873 shares in the last quarter. State Street Corp increased its position in Seattle Genetics by 18.3% in the first quarter. State Street Corp now owns 2,319,710 shares of the company’s stock valued at $81,406,000 after buying an additional 358,297 shares in the last quarter. Geode Capital Management LLC increased its position in Seattle Genetics by 7.9% in the first quarter. Geode Capital Management LLC now owns 711,458 shares of the company’s stock valued at $24,965,000 after buying an additional 52,065 shares in the last quarter. Finally, Bellevue Group AG bought a new position in Seattle Genetics during the first quarter valued at about $2,386,000. Hedge funds and other institutional investors own 97.21% of the company’s stock.

A number of analysts have recently weighed in on SGEN shares. Royal Bank Of Canada raised their price objective on Seattle Genetics from $55.00 to $62.00 and gave the stock an “outperform” rating in a research report on Monday, October 10th. Morgan Stanley started coverage on Seattle Genetics in a research report on Wednesday, September 7th. They issued an “overweight” rating and a $60.00 price objective for the company. Barclays PLC raised their price objective on Seattle Genetics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 27th. Leerink Swann raised their price objective on Seattle Genetics from $50.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, August 1st. Finally, RBC Capital Markets reissued an “outperform” rating and issued a $62.00 price objective (up previously from $55.00) on shares of Seattle Genetics in a research report on Monday, October 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $51.53.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

5 Day Chart for NASDAQ:SGEN

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.